Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours

Vinay Prasad

doi:10.3747/co.26.4845

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Letter

1 December 2019

Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours

Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA

Curr. Oncol.2019, 26(6), 791-792;https://doi.org/10.3747/co.26.4845

Version Notes

Order Reprints

Abstract

Although clinical trials of novel medications have historically been individually interpreted, there is increasing recognition that trials should be considered to be part of a broader clinical trials agenda or portfolio […]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

African–Caribbean Cancer Consortium Scientific and Training Conference 2017

Re: Countercurrents: Is Now the Right Time to Pull the Plug on Mammography?